Presentations

Documents

Order by : Name | Date | Hits [ Ascendant ]

Body fat distribution, insulin resistance and NASH Body fat distribution, insulin resistance and NASH

hot!
Date added: 08/05/2018
Date modified: 08/05/2018
Filesize: 8.89 MB
Downloads: 975

Oral presentation given by CNR at the Meeting Quadrisocietario Diabesità (SICOB, SID, SIE, SIO), Pisa, Italy, 5th - 6th October 2017

Fatty liver disease is associated to increased glucogenic amino acids and decreased de novo... Fatty liver disease is associated to increased glucogenic amino acids and decreased de novo...

hot!
Date added: 08/05/2018
Date modified: 08/05/2018
Filesize: 256 Bytes
Downloads: 749

"Fatty liver disease is associated to increased glucogenic amino acids and decreased de novo alanine synthesis"

Oral presentation given by CNR & UNITO at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD 2017), Lisbon, Portugal, 15th September 2017

P465L PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates P465L PPARγ mutation confers partial resistance to the hypolipidaemic action of fibrates

hot!
Date added: 07/28/2018
Date modified: 07/28/2018
Filesize: 1.42 MB
Downloads: 662

Poster presentation given by UCAM at the Conference: “Metabolism in Action - Lifetime influence of genes and environment”, organized by the Copenhagen Bioscience Conferences, a Novo Nordisk Foundation initiative, Hillerød, Denmark, 1st - 5th October 2017

Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 ‘FIB-C3 Score’ for Detection Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 ‘FIB-C3 Score’ for Detection

hot!
Date added: 07/28/2018
Date modified: 07/28/2018
Filesize: 256 Bytes
Downloads: 801

"Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 ‘FIB-C3 Score’ for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort"

Oral presentation given by UNEW, ICAN, UMC, UNITO & NB at the BASL Annual Meeting, Coventry, UK, 20th September 2017

Systems approaches to study obesity and metabolic co-morbidities Systems approaches to study obesity and metabolic co-morbidities

hot!
Date added: 07/28/2018
Date modified: 07/28/2018
Filesize: 256 Bytes
Downloads: 764

Oral presentation given by ORU at the 14th Key Symposium, Cambridge, UK, 20th September 2017

Metabolomics approaches to study NAFLD Metabolomics approaches to study NAFLD

hot!
Date added: 06/02/2018
Date modified: 06/02/2018
Filesize: 256 Bytes
Downloads: 889

Oral presentation given by ORU at the Federation of European Physiological Societies (FEPS) Congress, Vienna, Austria, 14th September 2017

NAFLD: Current & Future Therapeutic Approaches NAFLD: Current & Future Therapeutic Approaches

hot!
Date added: 06/02/2018
Date modified: 06/02/2018
Filesize: 256 Bytes
Downloads: 890

Oral presentation given by UNEW at the BASL School of Hepatology, Newcastle upon Tyne, UK, 28th June 2017

How common is NASH in your diabetes clinic? How common is NASH in your diabetes clinic?

hot!
Date added: 04/20/2018
Date modified: 04/20/2018
Filesize: 256 Bytes
Downloads: 925

Oral presentation given by UNITO at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017

NASH Therapeutics: Targets Under Evaluation in Early Phase Trials NASH Therapeutics: Targets Under Evaluation in Early Phase Trials

hot!
Date added: 04/20/2018
Date modified: 04/20/2018
Filesize: 256 Bytes
Downloads: 950

Oral presentation given by UNEW at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017

Why Should We Care About NAFLD? Why Should We Care About NAFLD?

hot!
Date added: 04/20/2018
Date modified: 04/20/2018
Filesize: 256 Bytes
Downloads: 923

Oral presentation given by UNEW at the 1st International Conference on Fatty Liver (ICFL), Seville, Spain, 1st - 3rd June 2017